Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lladó, A.
Right arrow Articles by Graus, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lladó, A.
Right arrow Articles by Graus, F.
Related Collections
Right arrow Peripheral neuropathy
Right arrow All Oncology
Right arrow Paraneoplastic syndrome
NEUROLOGY 2004;63:1947-1949
© 2004 American Academy of Neurology
Brief Communications

Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes

A. Lladó, MD, P. Mannucci, MD, A. F. Carpentier, MD, S. Paris, BSc, Y. Blanco, MD, A. Saiz, MD, J. Y. Delattre, MD and F. Graus, MD

From the Service of Neurology (Drs. Lladó, Mannucci, Blanco, Saiz, and Graus), Hospital Clínic, Universitat de Barcelona, and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona. Spain; and Service of Neurology (Drs. Carpentier and Delattre, S. Paris), Hôpital Salpêtrière, Unité INSERM 495, Paris, France.

Address correspondence and reprint requests to Dr. F. Graus, Service of Neurology, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain; e-mail: fgraus{at}clinic.ub.es

The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.

Received May 18, 2004. Accepted in final form July 9, 2004.




This article has been cited by other articles:


Home page
 BrainHome page
B. M. Ances, R. Vitaliani, R. A. Taylor, D. S. Liebeskind, A. Voloschin, D. J. Houghton, S. L. Galetta, M. Dichter, A. Alavi, M. R. Rosenfeld, et al.
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates
Brain, August 1, 2005; 128(8): 1764 - 1777.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.